Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck on Vioxx vs. Celebrex

Executive Summary

Vioxx (rofecoxib) continues to gain share in COX-2 inhibitor market, Merck says. Merck claims to hold a greater than 50% share of the Ob/Gyn, neurology, urology and dental specialty markets, with a 47% share of new prescriptions in the general practitioner market. New prescriptions for Vioxx in June were 900,000, Merck said. The product generated $375 mil. in U.S. sales during the quarter
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS036420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel